ASCO Living Guideline Reaffirms Endocrine Therapy as the Backbone of Early Breast Cancer Care
Endocrine therapy remains the central treatment for hormone receptor-positive, HER2-negative stage I-III breast cancer, and ASCO’s 2026 living guideline keeps that principle at the center of day-to-day oncology practice. The updated recommendations reflect a care pathway that begins at diagnosis and continues through the completion of systemic therapy, with treatment choices shaped by recurrence risk, tumor biology, patient preferences, and tolerability. In this disease subtype, the biology is often driven by estrogen signaling rather than HER2 amplification, so blocking hormonal stimulation is not an accessory maneuver. It is the foundation.
The guideline is built from a broad evidence review that identified 45 randomized clinical trials published between 2018 and 2026, along with six individual patient data meta-analyses and 21 retrospective studies. That evidence base was used to address who should receive treatment, which therapies should be selected, when they should be started, how long they should continue, and how adherence can be supported in routine care. The scope matters because decisions in early breast cancer are rarely isolated; they cascade from the first pathology report through years of surveillance and survivorship.
A single sentence captures the clinical direction: endocrine therapy remains the backbone of treatment.
Risk-Stratified Use of Chemotherapy and Targeted Therapy
Although endocrine therapy anchors care, the guideline does not reduce treatment to a one-size-fits-all template. For selected patients, chemotherapy and targeted therapies can further lower the risk of recurrence and breast cancer death. The key word is selected. Patients with stage I-III disease do not all carry the same recurrence hazard, and the evidence reviewed by the expert panel supports a more individualized approach than older, broader treatment habits sometimes allowed.
That is where clinicopathologic features and genomic assays enter the discussion. Tumor grade, nodal involvement, stage, and biomarker patterns all inform prognosis, while genomic testing helps refine the expected value of adding chemotherapy in appropriate candidates. The biologic rationale is straightforward: endocrine therapy suppresses the hormone-driven proliferative signal, while chemotherapy and selected targeted agents can reduce residual micrometastatic risk when the tumor’s features suggest a higher likelihood of occult spread. In practice, these choices are less about maximizing treatment intensity and more about matching therapeutic burden to the probability of benefit.
Patients and clinicians are being asked to make these decisions in an era when the harm-benefit balance is more visible than ever. Toxicity, quality of life, and treatment adherence are no longer secondary considerations tucked behind recurrence statistics. They are part of the therapeutic equation from the beginning.
Sequencing Decisions Now Span the Entire Course of Care
The guideline is organized to mirror the longitudinal sequence clinicians face in the clinic. That structure is clinically useful because treatment for early breast cancer is not a single event; it is a chain of choices. Neoadjuvant therapy may be used in some cases, adjuvant therapy in others, and the timing of endocrine treatment can affect both tolerability and persistence over time. The recommendations therefore address not only what to prescribe, but when to prescribe it and how to maintain adherence once treatment has begun.
This matters because endocrine therapy often extends over years. Even highly effective regimens fail when patients cannot stay on them, and the reasons are usually practical rather than mysterious: adverse effects, pill fatigue, competing medical problems, and the accumulated burden of long-term care. The panel’s attention to adherence is a reminder that real-world benefit depends on sustained exposure, not just initial prescription.
A brief but important clinical reality follows from that: benefit depends on persistence.
Prognosis and Benefit Estimation Shape Shared Decisions
The final section of the guideline addresses estimation of prognosis and treatment benefit. That addition changes the tone of treatment planning. Instead of asking only whether a therapy works in a population, clinicians are being guided to ask how much it is likely to help the individual patient sitting in front of them. In stage I-III disease, where many patients do well long term, the absolute benefit from chemotherapy or targeted therapy may be modest for some and substantial for others. The challenge is to identify those groups accurately enough to avoid both undertreatment and overtreatment.
Genomic assays and clinicopathologic risk assessment are therefore not competing frameworks. They are complementary tools. One measures tumor behavior through histologic and anatomic features; the other estimates biologic aggressiveness more directly. Used together, they can inform whether endocrine therapy alone is sufficient or whether escalation is justified. The recommendation to integrate patient preferences into this process is equally important. Some patients will accept more short-term toxicity to reduce recurrence risk, while others will prioritize avoiding treatment burden when the expected absolute gain is limited.
What This Means at the Bedside
For oncologists, the most immediate message is continuity: stage I-III hormone receptor-positive, HER2-negative breast cancer should be approached as a longitudinal disease process in which systemic therapy is tailored rather than reflexively intensified. The guideline supports endocrine therapy as the standard starting point and reserves chemotherapy or targeted therapy for patients whose recurrence risk and biologic features justify escalation. That approach is consistent with the fundamental biology of this subtype, where hormonal signaling drives much of the disease behavior and sustained suppression can translate into durable risk reduction.
For patients, the practical implication is equally direct. Treatment planning should account for recurrence risk, potential toxicity, and the likelihood that a given regimen can actually be completed. The expert panel’s evidence review also confirms that the best decision is not always the most aggressive one. In many cases, the most effective strategy is the one that balances benefit against tolerability and can be maintained over time.
The living guideline format signals that this area will keep changing as new randomized trials, meta-analyses, and real-world studies emerge. The current recommendations are grounded in evidence published through 2026, but they remain tied to the limitations of the available data, especially where retrospective analyses and indirect comparisons inform practice. Future updates will need to refine how genomic assays, recurrence estimation, and treatment duration are used together, particularly as clinicians continue trying to narrow who truly benefits from therapy escalation and who can safely avoid it.